AMERICAN SKIN ASSOCIATION ANNUAL GALA CELEBRATES OUTSTANDING HONOREES
SNY(NASDAQ:SNY) Gala honors Renowned Surgeon Jesse M. Lewin, MD, FAAD, FACS and Global Pharmaceutical Leader Sanofi NEW YORK, Sept. 11, 2025 /PRNewswire/ -- On Wednesday evening, at The Plaza Hotel, American Skin Association (ASA) held their Annual Gala. They presented awards to two outstanding honorees...
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
SNY(NASDAQ:SNY) Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
SNY(NASDAQ:SNY) Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
SNY(NASDAQ:SNY) Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
SNY(NASDAQ:SNY) Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi: Information concerning the total number of voting rights and shares - July 2025
SNYInformation concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
SNYSanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
The Department of Health - Abu Dhabi and Sanofi Forge Strategic Alliance to Accelerate the Development of New Global Vaccines in Abu Dhabi
SNYOn the sidelines of a high-level US visit focused on healthcare innovation ABU DHABI, UAE, June 18, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has signed a Memorandum of Understanding (MoU) with Sanofi, a research...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
SNYNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm
SNYLOS ANGELES--(BUSINESS WIRE)---- $SNY--SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm
Sanofi Launches 2025 Global Employee Stock Purchase Plan Offering Shares At €72.97 With 20% Discount And Matching Incentive
SNYSanofi Announces New Data Shows Subcutaneous Sarclisa Delivered Via On-Body Injector Cuts Treatment Time To Minutes While Maintaining Efficacy And Safety, At ASCO 2025
SNYSanofi's Rilzabrutinib Receives Fourth Orphan Drug Designation In The US, Targeting Vaso-Occlusive Crises In Sickle Cell Disease
SNYSanofi Opens New $130M Offices In Morristown, NJ
SNYSanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition
SNYSanofi (SNY) to acquire Vigil Neuroscience (VIGL) for $470 million in cash, plus potential $2 per share payout. Acquisition excludes monoclonal antibody program and is expected to be finalized in Q3 2025. VG-3927 showed promise in Phase 1 for Alzheimer's treatment.
Reported Earlier, Sanofi To Acquire Vigil Neuroscience In $470M Deal, Boosting Neurology Pipeline With Investigational Alzheimer's Medicine
SNYPrice Over Earnings Overview: Sanofi
SNYSanofi Intends To Invest At Least $20B In US Through 2030, Growing Investments In Science And Expanding Domestic Manufacturing
SNYSanofi Closed Sale Of 50% Stake In Opella To CD&R For €10B
SNYSanofi Reaffirms 2025 Guidance: Sales To Grow Mid-To-High Single Digits (CER), Business EPS To Rise Low Double Digits (CER)
SNYSanofi Q1 Adj. EPS $0.94 Misses $0.95 Estimate, Sales $10.41B Beat $9.77B Estimate
SNYEarendil Labs And Sanofi Entered Into A License Agreement For Two Bispecific Antibodies In The Field Of Autoimmune And Inflammatory Bowel Diseases, HXN-1002 and HXN-1003, For An Upfront Payment Of $125M And $1.72B In Milestone Payments
SNYSanofi's Amlitelimab Shows Clinically Meaningful Efficacy In Phase 2 Asthma Study, Phase 3 Program In Planning
SNYHow Do Investors Really Feel About Sanofi?
SNYWhy Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
SNYSanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response rates and reduced disease flares.
FDA Grants Orphan Drug Status To Sanofi's Rilzabrutinib For Two Rare Autoimmune Diseases With High Unmet Needs
SNYSanofi's Chlamydia Vaccine Candidate Receives FDA Fast Track Designation
SNYSanofi's Tolebrutinib Granted FDA Priority Review For Non-Relapsing Secondary Progressive MS, Targeting Smoldering Neuroinflammation
SNYGoldman Sachs Initiates Coverage On Sanofi with Neutral Rating, Announces Price Target of $65
SNYSanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal
SNYSanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with a promising bispecific antibody.
Sanofi To Acquire Dren Bio's DR-0201 For $600M Upfront, With Up To $1.3B In Milestone Payments
SNYSanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
SNYSanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.
Sanofi Gains Japanese Approval For Sarclisa In Newly Diagnosed Multiple Myeloma Patients
SNYSanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
SNYTeva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.
Reported Saturday, Teva and Sanofi Presented Phase 2b Data At ECCO 2025, Highlighting Duvakitug's Promise For Ulcerative Colitis And Crohn's Disease
SNYSanofi And CD&R Finalize Share Purchase Agreement For 50% Stake In Opella
SNYSoros Fund Management Cuts Share Stake In Sanofi By 50% To 200,000 Sponsored ADRs
SNYHow Is The Market Feeling About Sanofi?
SNYSanofi's Sarclisa Gains First Approval In China, Expanding Access For Patients With Relapsed Or Refractory Multiple Myeloma
SNYPrice Over Earnings Overview: Sanofi
SNYSanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma
SNYSanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.
Sanofi's Sarclisa Subcutaneous Formulation Achieves Co-Primary Endpoints In IRAKLIA Phase 3 Trial For Multiple Myeloma Treatment
SNYA Look Into Sanofi Inc's Price Over Earnings
SNYSanofi Launches Phase 3 Trials For PCV21 And Strengthens Partnership With SK Bioscience On Next-Generation Pneumococcal Conjugate Vaccines
SNYSarclisa Recommended For EU Approval By The CHMP To Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma; Sarclisa Recommended For EU Approval By CHMP; Sarclisa Could Be First Anti-CD38 Therapy In EU For NDMM
SNYSanofi New Results From Rilzabrutinib Phase 2 Study Show Potential To Be First Advanced Oral Treatment For Moderate-To-Severe Asthma; Data Shows Rilzabrutinib Led To Numerical Reduction In Loss Of Asthma Control Events, Improvement In Symptoms And Was Wel
SNYSanofi, Formation Bio, And OpenAI Collaborate To Develop AI-Powered Software, Accelerating Drug Development And Enhancing Patient Access To New Medicines
SNY'Executive Order: Declaring A Disaster In The State Of New York'
SNY'New York declares state of emergency over polio to boost vaccination rate' -CNBC Report
SNYDupixent, Consumer Healthcare Lifts Sanofi's Q1 Earnings, Backs FY22 Guidance
SNY